Intersect ENT Inc (NASDAQ:XENT) was the target of some unusual options trading on Tuesday. Traders bought 1,568 call options on the company. This is an increase of 1,662% compared to the average volume of 89 call options.
Shares of XENT stock opened at $18.11 on Thursday. Intersect ENT has a 12-month low of $15.01 and a 12-month high of $35.87. The stock’s 50-day moving average price is $16.82 and its 200-day moving average price is $24.41. The stock has a market capitalization of $576.58 million, a price-to-earnings ratio of -23.83 and a beta of 0.73.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.02). Intersect ENT had a negative return on equity of 29.16% and a negative net margin of 31.43%. The firm had revenue of $26.66 million during the quarter, compared to the consensus estimate of $27.13 million. During the same period last year, the firm posted ($0.14) earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, research analysts forecast that Intersect ENT will post -1.44 EPS for the current fiscal year.
A number of equities research analysts have commented on XENT shares. Berenberg Bank cut Intersect ENT from a “buy” rating to a “hold” rating and decreased their price target for the company from $35.00 to $27.00 in a report on Friday, June 21st. ValuEngine raised Intersect ENT from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Northland Securities raised Intersect ENT from an “under perform” rating to a “market perform” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. Guggenheim cut Intersect ENT from a “buy” rating to a “neutral” rating in a report on Friday, August 2nd. Finally, BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company’s stock. Intersect ENT currently has an average rating of “Hold” and a consensus target price of $27.11.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.